Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nbi Biosciences Private Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and is located in 1 distinct art unit. The company's current pending workload is concentrated in this single technical classification.
The busiest examiner for the portfolio is MOREAU, NASHARA LOUISE, who is managing 1 pending office action. This 1 action represents the total pending workload for the company. Because MOREAU, NASHARA LOUISE is the only examiner involved, the prosecution strategy is centered on this individual's evaluation of the 1 pending application.
For a practitioner, having 1 distinct examiner and 1 distinct art unit simplifies the management of the pending portfolio. The company can focus its efforts on the specific examination practices of MOREAU, NASHARA LOUISE. This streamlined approach allows for a clear focus on the technical issues raised in the 1 pending office action without the need to coordinate across different art units or multiple examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 80.0% | -100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005721 | ANTI-HYPERCHOLESTEROLEMIA COMPOSITION AND A METHOD OF MANUFACTURING THE SAME | MOREAU, NASHARA LOUISE | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18005721 | ANTI-HYPERCHOLESTEROLEMIA COMPOSITION AND A METHOD OF MANUFACTURING THE SAME | MOREAU, NASHARA LOUISE | 1655 | §101§103 | Final Rejection | 46d overdue | Pending | Jan 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial